Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MEGESTROL-ACETATE FOR THE PREVENTION OF HOT FLASHES
Autore:
LOPRINZI CL; MICHALAK JC; QUELLA SK; OFALLON JR; HATFIELD AK; NELIMARK RA; DOSE AM; FISCHER T; JOHNSON C; KLATT NE; BATE WW; ROSPOND RM; OESTERLING JE;
Indirizzi:
MAYO CLIN & MAYO FDN,DEPT ONCOL,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT UROL ROCHESTER MN 55905 SIOUXLAND HEMATOL ONCOL ASSOCIATES SIOUX CITY IA 00000 CARLE CANC CTR,COMMUNITY CLIN ONCOL PROGRAM URBANA IL 00000 QUAIN & RAMSTAD CLIN BISMARCK ND 00000 ST LUKES HOSP,COMMUNITY CLIN ONCOL PROGRAM FARGO ND 00000 GRAND FORKS CLIN LTD GRAND FORKS ND 00000 IOWA ONCOL RES ASSOC,COMMUNITY CLIN ONCOL PROGRAM DES MOINES IA 00000 CREIGHTON UNIV,NEBRASKA ONCOL GRP OMAHA NE 68178 UNIV NEBRASKA,MED CTR OMAHA NE 00000
Titolo Testata:
The New England journal of medicine
fascicolo: 6, volume: 331, anno: 1994,
pagine: 347 - 352
SICI:
0028-4793(1994)331:6<347:MFTPOH>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROSTATIC-CANCER; BREAST-CANCER; MEDROXYPROGESTERONE ACETATE; ORAL MEDROXYPROGESTERONE; FLUSHES; THERAPY; SYMPTOMS; HORMONE; TRIAL; ORCHIDECTOMY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
C.L. Loprinzi et al., "MEGESTROL-ACETATE FOR THE PREVENTION OF HOT FLASHES", The New England journal of medicine, 331(6), 1994, pp. 347-352

Abstract

Background. Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapyfor prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostrate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of patients. Methods. The patients included 97 women with a history of breast cancer and 66 men with prostate cancer who had undergone androgen-deprivation therapy. All patients had experienced bothersome hot flashes (median number per day at base line, 6.1 for the women and 8.4 for the men). After a one-week pretreatment observation period, the patients received megestrol acetate (20 mg twice dally) for four weeks, followed by placebo for four weeks, or vice versa in a double-blind manner as determined by pretreatment randomization. The patients documented the frequency and severity of hot flashes in daily symptom diaries. Results. Afterfour weeks, hot flashes were reduced by 21 percent in the group receiving placebo first and by 85 percent in the group receiving megestrol acetate first (P<0.001). An intention-to-treat analysis of data for all eligible treated patients showed that 74 percent of the megestrol acetate group, as compared with 20 percent of the placebo group, had a decrease of 50 percent or more in the frequency of hot flashes during the first four weeks (P<0.001). The degree of efficacy was similar in men and women. The only side effect was withdrawal menstrual bleeding in women, generally occurring one to two weeks after the megestrol acetate had been discontinued.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 09:01:55